Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16912)	6/11/2004 5:26:57 PM
From: Bluegreen	Respond to of 17367

George, the FDA didn't clear Cytolin study for just post exposure, prevention. AND isn't Cytolin the old mouse version of anti-lfa-1??? Notice these are actually AIDS patients.>>>>>>>>http://www.hivpositive.com/f-Treatment/5-Treatments/f-Immunology/CytolinTest.html

To: aknahow who wrote (16912)	6/11/2004 5:36:20 PM
From: Bluegreen	Respond to of 17367

George from my last post>>>>>>>>Although CytoDyn does not control this experimental use of Cytolin, medical records from four doctors shared with the company and submitted to the FDA show that at the end of 1995, they had treated 188 patients with Cytolin for a total of about 700 times for periods up to two years.<<<<<< Do you think these four doctors got sued? Do you think these four doctors and others like them would like to prescribe Raptiva off label? BTW, what about physicians running clinics outside the USA?